BSE filing, NSE: ASPIRA. Summary written from the filing by ALFA Finder's alert engine.
Aspira Pathlab & Diagnostics Ltd: key numbers
- Share price
- ₹128.00
- Market cap
- ₹131.8 Cr
- Revenue (annual)
- ₹24.98 Cr
- Net profit (annual)
- ₹0.05 Cr
- P/E (TTM)
- -291.1×Sector 51.1×
- Promoter holding
- 46.65%+0.07% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aspira Pathlab & Diagnostics Ltd
All →Aspira Pathlab & Diagnostics Promoter Buying: ₹0.02 Cr
Promoter Jay Arvind Bhanushali acquired 1,424 equity shares of Aspira Pathlab & Diagnostics Ltd via market purchase. The transaction is valued at ₹0.02 Crore.
- Value
- ₹0.02 Cr
- Promoter stake change
- +0.01%
Aspira Pathlab & Diagnostics Promoter Buying
Promoter Jay Arvind Bhanushali acquired 1,424 shares of Aspira Pathlab & Diagnostics Ltd via the open market. This transaction increased the promoter's stake from 7.27% to 7.28%.
- Execution
- 17-09-2026 to 24-09-2026
- Promoter stake change
- +0.01%
Aspira Pathlab & Diagnostics Annual General Meeting
Aspira Pathlab & Diagnostics held its 53rd Annual General Meeting on September 25, 2026, where members deliberated on financial statements and various directorial appointments.
Aspira Pathlab & Diagnostics Promoter Buying: ₹0.01 Cr
Promoter Jay Arvind Bhanushali acquired 1,387 equity shares of Aspira Pathlab & Diagnostics Ltd through market purchase, increasing their stake from 7.25% to 7.27%.
- Value
- ₹0.01 Cr
- Promoter stake change
- +0.02%
Aspira Pathlab & Diagnostics Promoter Buying
Promoter Jay Arvind Bhanushali acquired 1,387 shares of Aspira Pathlab & Diagnostics Ltd via an open-market transaction, increasing his stake by 0.02%.
- Promoter stake change
- +0.02%
Aspira Pathlab & Diagnostics Promoter Buying: ₹0 Cr
Promoter Jay Arvind Bhanushali acquired 74 shares of Aspira Pathlab & Diagnostics Ltd via market purchase on September 10, 2026.
- Value
- ₹0.00 Cr
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.